Conversion to monotherapy

Also known as: Conversion to mono therapy

Drug	Drug Name	Drug Description
DB00555	Lamotrigine	A phenyltriazine antiepileptic used to treat some types of epilepsy and bipolar I disorder.

Drug	Drug Name	Target	Type
DB00555	Lamotrigine	Voltage-gated sodium channel alpha subunit	target
DB00555	Lamotrigine	UDP-glucuronosyltransferases (UGTs)	enzyme
DB00555	Lamotrigine	P-glycoprotein 1	transporter
DB00555	Lamotrigine	Dihydrofolate reductase	enzyme
DB00555	Lamotrigine	5-hydroxytryptamine receptor 3A	target
DB00555	Lamotrigine	Voltage-dependent R-type calcium channel subunit alpha-1E (CACNA1E)	target
DB00555	Lamotrigine	Adenosine receptor A1	target
DB00555	Lamotrigine	Adenosine receptor A2a	target
DB00555	Lamotrigine	Alpha-1A adrenergic receptor	target
DB00555	Lamotrigine	Alpha-2A adrenergic receptor	target
DB00555	Lamotrigine	Beta-1 adrenergic receptor	target
DB00555	Lamotrigine	D(1) dopamine receptor	target
DB00555	Lamotrigine	Dopamine D2 receptor	target
DB00555	Lamotrigine	GABA(A) Receptor	target
DB00555	Lamotrigine	GABA(A) Receptor Benzodiazepine Binding Site	target
DB00555	Lamotrigine	Histamine H1 receptor	target
DB00555	Lamotrigine	Kappa-type opioid receptor	target
DB00555	Lamotrigine	Acetylcholine receptor subunit alpha	target
DB00555	Lamotrigine	5-hydroxytryptamine receptor 2A	target
DB00555	Lamotrigine	Solute carrier family 22 member 2	transporter
DB00555	Lamotrigine	Serum albumin	carrier
DB00555	Lamotrigine	Solute carrier family 22 member 1	transporter
DB00555	Lamotrigine	Glutamate receptor 1	target

Drug	Drug Name	Phase	Status	Count